GlassScriptPhysician profile
Frantz Francisque
NPI 1902217953
$20,485.54
in general payments reported to CMS, 2019-2025
70 companies · $8,543 in 2025
The $8,543 reported for 2025 was more than what 87% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $850 · 2023: $5,494 · 2024: $5,598 · 2025: $8,543.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Consulting Fee: $2,080 · Long Term Medical Supply Or Device Loan: $682 · Travel and Lodging: $619 · Education: $604 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,425.46 |
| Consulting Fee | $2,080.00 |
| Long Term Medical Supply Or Device Loan | $681.53 |
| Travel and Lodging | $619.30 |
| Education | $603.83 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $225.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Geron Corporation | $2,933.29 | 2025 | Imetelstat, Rytelo |
| Novartis Pharmaceuticals Corporation | $2,068.79 | 2022-2025 | |
| Celgene Corporation | $1,473.42 | 2023-2025 | Reblozyl, Opdualag |
| Astrazeneca Pharmaceuticals LP | $990.28 | 2022-2025 | Enhertu, Calquence, Imfinzi |
| Pfizer INC. | $868.63 | 2022-2025 | |
| Astellas Pharma US INC | $839.50 | 2022-2025 | Padcev, Xospata, Vyloy |
| Bayer Healthcare Pharmaceuticals INC. | $733.32 | 2022-2025 | |
| Gilead Sciences, INC. | $684.92 | 2022-2025 | Trodelvy |
| Janssen Biotech, INC. | $667.03 | 2022-2025 | Rybrevant, Erleada, Carvykti |
| E.R. Squibb & Sons, L.L.C. | $624.09 | 2023-2025 | Opdivo, Opdualag, Reblozyl |
| Merck Sharp & Dohme LLC | $619.05 | 2022-2025 | Keytruda, Lynparza |
| Eisai INC. | $582.35 | 2022-2025 | |
| Daiichi Sankyo INC. | $548.66 | 2022-2025 | Enhertu, Vanflyta, Datroway |
| Incyte Corporation | $456.32 | 2022-2025 | Jakafi, Monjuvi, Zynyz |
| Tempus Ai, INC | $443.58 | 2024-2025 | Xt Cdx |
Show all 70 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $429.11 | 2023-2025 | Ojjaara, Zejula, Jemperli |
| Regeneron Healthcare Solutions, INC. | $408.35 | 2023-2025 | Libtayo, Lynozyfic |
| Emd Serono, INC. | $393.06 | 2022-2025 | Bavencio |
| Lilly USA, LLC | $363.79 | 2022-2025 | Verzenio, Jaypirca, Retevmo |
| Genentech USA, INC. | $278.04 | 2022-2025 | Tecentriq, Polivy, Phesgo |
| Fennec Pharmaceuticals, INC. | $273.44 | 2024-2025 | Fyarro, Pedmark |
| Array Biopharma INC | $252.45 | 2023-2025 | Braftovi, Mektovi, Lorbrena |
| Abbvie INC. | $240.74 | 2024-2025 | |
| Seagen INC. | $234.89 | 2022-2023 | Tukysa, Padcev |
| Kite Pharma, INC. | $231.58 | 2023-2025 | Yescarta |
| Beigene USA, INC. | $191.87 | 2023-2025 | Brukinsa, Tevimbra |
| Takeda Pharmaceuticals U.S.A., INC. | $190.55 | 2023-2025 | Fruzaqla, Iclusig |
| Genzyme Corporation | $147.77 | 2022-2025 | |
| Karyopharm Therapeutics INC. | $138.16 | 2022-2025 | Xpovio |
| Sun Pharmaceutical Industries INC. | $128.36 | 2022-2025 | |
| Aveo Pharmaceuticals, INC. | $126.60 | 2022-2025 | Fotivda |
| Sobi, INC | $115.94 | 2023-2025 | |
| Celltrion USA INC. | $114.22 | 2023 | Vegzelma |
| Pharmacosmos Therapeutics INC. | $112.38 | 2023-2025 | Monoferric, Cosela |
| Rigel Pharmaceuticals, INC. | $102.90 | 2022-2023 | Rezlidhia, Tavalisse |
| Servier Pharmaceuticals LLC | $99.21 | 2023-2025 | |
| Puma Biotechnology, INC. | $95.71 | 2022-2025 | Nerlynx |
| G1 Therapeutics, INC. | $88.08 | 2022-2023 | Cosela |
| Stemline Therapeutics INC. | $86.26 | 2023-2025 | Orserdu |
| Sumitomo Pharma America, INC. | $77.74 | 2023-2025 | Orgovyx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.24 | 2024-2025 | Gilotrif |
| Kyowa Kirin, INC. | $66.76 | 2024-2025 | Poteligeo |
| Pharmaessentia USA Corporation | $65.03 | 2025 | Besremi |
| Jazz Pharmaceuticals INC. | $61.02 | 2023-2025 | Zepzelca |
| Mirati Therapeutics, INC. | $60.43 | 2023-2024 | Krazati |
| Verity Pharmaceuticals INC. | $59.83 | 2022-2025 | Trelstar |
| Pharmacyclics LLC, An Abbvie Company | $52.36 | 2023 | Imbruvica |
| Springworks Therapeutics, INC. | $51.41 | 2024-2025 | Ogsiveo |
| Genmab U.S., INC. | $50.93 | 2023-2025 | Epkinly |
| Beone Medicines USA, INC. | $48.83 | 2025 | Tevimbra, Brukinsa |
| Ipsen Biopharmaceuticals, INC | $39.32 | 2023-2024 | Onivyde, Somatuline Depot |
| Taiho Oncology, INC. | $39.00 | 2024-2025 | |
| Tersera Therapeutics LLC | $37.04 | 2025 | Zoladex |
| Janssen Scientific Affairs, LLC | $31.58 | 2025 | Imbruvica, Talvey, Tecvayli |
| Caris Mpi, INC. | $23.51 | 2025 | Mi Cancer Seek |
| Legend Biotech USA INC. | $23.43 | 2025 | Carvykti |
| Telix Pharmaceuticals | $22.00 | 2023 | Illuccix |
| Alnylam Pharmaceuticals INC. | $21.00 | 2023 | Givlaari |
| Deciphera Pharmaceuticals INC. | $20.84 | 2025 | Qinlock, Romvimza |
| Morphosys, US INC. | $20.00 | 2023 | Monjuvi |
| Blueprint Medicines Corporation | $19.80 | 2024 | Ayvakit |
| Accord Healthcare, INC. | $17.40 | 2022 | |
| Amneal Pharmaceuticals LLC | $17.37 | 2024 | Avastin |
| Acrotech Biopharma INC. | $17.18 | 2024 | Ryzneuta |
| Agios Pharmaceuticals, INC. | $16.25 | 2024 | Pyrukynd |
| Heron Therapeutics, INC. | $16.07 | 2023 | Cinvanti |
| Menarini Silicon Biosystems, INC. | $15.96 | 2025 | |
| Azurity Pharmaceuticals, INC. | $13.96 | 2025 | Danziten |
| Amgen INC. | $13.60 | 2023 | Vectibix |
| Myovant Sciences INC. | $11.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frantz Francisque listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.